Ib/II Phase Study of SHR-A1811 Injection in HER2 Positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and efficacy of SHR-A1811 combined with pyrrolidone or
patrozumab or SHR-1316 or albumin paclitaxel in patients with HER2 positive non resectable or
metastatic breast cancer.